Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Cellular Vaccine for Brain Metastases
NCT02808416Phase 1Completed
- Sponsor
- Guangdong Sanjiu Brain Hospital
- Start
- Mar 2016
- Primary completion
- Oct 2017
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rocapuldencel-T in brain metastases, sponsored by Guangdong Sanjiu Brain Hospital. Primary endpoint: Incidence of treatment-emergent adverse events and severe adverse events at 3 years. Started Mar 2016; status: completed.
02
Drugs
rocapuldencel-T
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT02808416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02808416.